Stocks
Allogene Therapeutics Financial Statements (ALLO) |
||||||||||
| Allogene Therapeuticssmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 03.05.2023 | 02.08.2023 | 02.11.2023 | 14.03.2024 | 13.05.2024 | 13.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.052 | 0.044 | 0.043 | 0.021 | 0.022 | 0.130 | |||
| Operating Income, bln rub | -99.1 | -80.5 | -63.0 | -71.9 | -69.5 | -284.9 | ||||
| EBITDA, bln rub | ? | -99.1 | -76.9 | -59.4 | -68.5 | -65.9 | -270.7 | |||
| Net profit, bln rub | ? | -98.3 | -78.0 | -61.3 | -85.8 | -65.0 | -290.1 | |||
| OCF, bln rub | ? | -66.6 | -61.9 | -55.5 | -53.7 | -55.9 | -227.0 | |||
| CAPEX, bln rub | ? | 1.04 | 0.288 | 0.012 | 0.181 | 0.008 | 0.489 | |||
| FCF, bln rub | ? | -67.7 | -62.1 | -55.5 | -53.9 | -55.9 | -227.5 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 99.1 | 80.6 | 63.0 | 71.9 | 66.0 | 281.4 | ||||
| Cost of production, bln rub | 3.71 | 3.79 | 3.57 | 54.7 | 3.56 | 65.6 | ||||
| R&D, bln rub | 80.2 | 62.0 | 46.0 | 54.7 | 48.7 | 211.4 | ||||
| Interest expenses, bln rub | 0.366 | 0.000 | 0.000 | 0.366 | 0.000 | 0.366 | ||||
| Assets, bln rub | 746.9 | 771.0 | 712.3 | 642.8 | 586.4 | 586.4 | ||||
| Net Assets, bln rub | ? | 592.3 | 622.9 | 583.1 | 512.2 | 461.4 | 461.4 | |||
| Debt, bln rub | 99.7 | 91.8 | 90.1 | 95.1 | 95.8 | 95.8 | ||||
| Cash, bln rub | 514.0 | 492.0 | 465.5 | 448.7 | 384.9 | 384.9 | ||||
| Net debt, bln rub | -414.3 | -400.1 | -375.4 | -353.6 | -289.0 | -289.0 | ||||
| Ordinary share price, rub | 4.94 | 4.97 | 3.17 | 3.21 | 4.47 | 2.97 | ||||
| Number of ordinary shares, mln | 144.6 | 146.8 | 167.6 | 168.3 | 169.1 | 169.1 | ||||
| Market cap, bln rub | 714 | 730 | 531 | 540 | 756 | 502 | ||||
| EV, bln rub | ? | 300 | 329 | 156 | 187 | 467 | 213 | |||
| Book value, bln rub | 592 | 623 | 583 | 512 | 461 | 461 | ||||
| EPS, rub | ? | -0.68 | -0.53 | -0.37 | -0.51 | -0.38 | -1.72 | |||
| FCF/share, rub | -0.47 | -0.42 | -0.33 | -0.32 | -0.33 | -1.35 | ||||
| BV/share, rub | 4.10 | 4.24 | 3.48 | 3.04 | 2.73 | 2.73 | ||||
| EBITDA margin, % | ? | -190 519% | -174 716% | -138 147% | -325 962% | -299 768% | -208 215% | |||
| Net margin, % | ? | -189 112% | -177 248% | -142 593% | -408 467% | -295 455% | -223 140% | |||
| FCF yield, % | ? | -31.3% | -33.1% | -46.9% | -44.3% | -30.1% | -45.3% | |||
| ROE, % | ? | -58.8% | -56.5% | -56.8% | -63.1% | -62.9% | -62.9% | |||
| ROA, % | ? | -46.6% | -45.6% | -46.5% | -50.3% | -49.5% | -49.5% | |||
| P/E | ? | -2.05 | -2.07 | -1.61 | -1.67 | -2.61 | -1.73 | |||
| P/FCF | -3.20 | -3.02 | -2.13 | -2.26 | -3.32 | -2.21 | ||||
| P/S | ? | 3 052 | 3 800 | 2 857 | 3 377 | 5 815 | 3 864 | |||
| P/BV | ? | 1.21 | 1.17 | 0.91 | 1.05 | 1.64 | 1.09 | |||
| EV/EBITDA | ? | -0.86 | -0.94 | -0.47 | -0.61 | -1.73 | -0.79 | |||
| Debt/EBITDA | 1.19 | 1.14 | 1.13 | 1.16 | 1.07 | 1.07 | ||||
| R&D/CAPEX, % | 7 752% | 21 541% | 383 142% | 30 199% | 608 800% | 43 227% | ||||
| CAPEX/Revenue, % | 1 990% | 654.5% | 27.9% | 861.9% | 36.4% | 376.2% | ||||
| Allogene Therapeutics shareholders | ||||||||||
